European medical device company ViCentra, developer of the Kaleido insulin patch pump system, has announced the second close of its Series D financing round, adding 13 million USD and increasing the total round to 98 million USD.
The additional funding includes new capital from ROM Utrecht Region and a consortium of Dutch investors, including Venturing Tech, alongside increased support from existing investor Innovation Industries. With this funding, ViCentra says it will scale manufacturing, deepen commercial execution in Germany, the Netherlands, and France, and accelerate preparations for its ‘next-generation’ Kaleido insulin patch pump for U.S. Market access.
This follows the successful 85 million USD raised in September 2025, and according to ViCentra, well positions the company to accelerate growth and build leadership in the insulin delivery market. The company claims that Kaleido is the smallest, lightest, and most precise insulin patch pump in its class.
“The past year has been transformative for ViCentra. This latest funding enables us to further scale our manufacturing capabilities, strengthen our commercial presence and support in Germany, the Netherlands, and France, and ensures that we remain on course for our planned U.S. market access. Our goal for 2026 is clear: convert our current high demand into satisfied users through uncompromising quality and performance and nearly triple our European user base by the end of 2026,” said Tom Arnold, Chief Executive Officer of ViCentra.
